SlideShare a Scribd company logo
1 of 8
Download to read offline
29 October 2014 
2QFY15 Results Update | Sector: Media 
Jagran Prakashan 
Shobhit Khare (Shobhit.Khare@MotilalOswal.com); +91 22 3982 5428 
BSE SENSEX 
S&P CNX 
CMP: INR127 
TP: INR165 
Buy 
27,098 
8,090 
Bloomberg 
JAGP IN 
Equity Shares (m) 
326.9 
M.Cap. (INR b) / (USD b) 
41.6/0.7 
52-Week Range (INR) 
140/79 
1, 6, 12 Rel. Per (%) 
1/0/22 
Financials & Valuation (INR Million) 
Y/E MAR 
2015E 
2016E 
2017E 
Net Sales 
18.3 
20.3 
22.2 
EBITDA 
4.5 
5.2 
5.7 
Net Profit 
2.4 
3.0 
3.4 
EPS (INR) 
7.7 
9.5 
11.0 
EPS Gr. (%) 
20.1 
23.2 
16.0 
BV/Sh(INR) 
34.0 
38.8 
45.1 
RoE (%) 
23.8 
26.1 
26.3 
RoCE (%) 
16.8 
18.8 
19.6 
D.payout(%) 
60.7 
49.3 
42.5 
Valuations 
P/E (x) 
16.5 
13.4 
11.5 
P/BV (x) 
3.7 
3.3 
2.8 
EV/EBITDA (x) 
9.1 
7.7 
6.7 
D. Yield (%) 
3.1 
3.1 
3.1 
 JAGP’s 2QFY15 EBITDA grew 16% YoY to INR1.06b (vs est of INR1.04b), supported by high single-digit growth in print advertising/circulation revenue and lower ‘other expenses’. 
 PAT grew 24% YoY to INR566m led by strong operating performance and higher other income, though offset by increased tax rate on a YoY basis. Tax rate increased 720bp YoY to 31% as the base period included tax benefits pertaining to the ‘Nai Duniya’ acquisition. 
 Ad revenue increased 8% YoY to INR3.07b (vs est of INR3.07b). Circulation revenue grew 7% YoY to INR965m (vs estimate of INR992m). 
 Consolidated revenue grew 5.4% YoY to INR4.36b (vs estimate of INR4.46b). The shortfall was largely on account of lower revenues from non-print segment. 
 Consolidated EBITDA margin increased 220bp YoY to 24.4%. RM cost increased ~9% YoY to INR1.6b (36.7% of revenue). We expect newsprint prices to correct going forward. 
 Other expenses declined 8% YoY on overall opex control, lower direct expenses in outdoor/event/digital and lower write-off/provision for bad debts. 
Valuation and view 
 Jagran’s 2QFY15 performance was broadly in line. We continue to expect strong earnings rebound in 2HFY15 led by acceleration in ad growth and decline in newsprint prices vs current levels. 
 We are upgrading PAT estimates by 1-3% on higher margin assumptions. We expect proforma EPS CAGR of 19% over FY14-17E driven by 10% ad revenue CAGR and EBITDA margin expansion of ~310 bps. 
 The stock trades at P/E of 16.5x FY15E and 13.4x FY16E. Maintain Buy with a price target of INR165 based on 16x average FY16/17 EPS. 
Investors are advised to refer through disclosures made at the end of the Research Report.
29 October 2014 2 
Jagran Prakashan 
Standalone ad/circulation revenue (including Nai Duniya from 4QFY13) 
Source: Company, MOSL 
Standalone YoY ad growth (%) 
Source: Company, MOSL 
Standalone EBITDA (incl Nai Duniya from 4QFY13) 
Source: Company, MOSL 
RM/Sales (Consolidated from 1QFY14) 
Source: Company, MOSL 
1,8981,9351,9451,8872,0432,1192,2352,1032,2072,1962,3932,2762,6852,6303,0002,6472,8802,8665535485705595826126236286416666997617958268618608969081QFY112QFY113QFY114QFY111QFY122QFY123QFY124QFY121QFY132QFY133QFY134QFY131QFY142QFY143QFY144QFY141QFY152QFY15 Advertising revenue (INR m)Circulation revenue (INR m) 18133120810151184701211151679 1QFY112QFY113QFY114QFY111QFY122QFY123QFY124QFY121QFY132QFY133QFY134QFY131QFY142QFY143QFY144QFY141QFY152QFY157058326536339029088977148207918516597887829115401013911109079710591033 30342927333331252726262125242616262425202625 1QFY102QFY103QFY104QFY101QFY112QFY113QFY114QFY111QFY122QFY123QFY124QFY121QFY132QFY133QFY134QFY131QFY142QFY143QFY144QFY141QFY152QFY15 EBITDA (INR m)EBITDA margin (%) 7016846746787568018639119891,0751,1351,0821,1351,1091,1791,2401,4161,4731,6271,5711,6271,603 30283029282930323235353536343436343636373737 1QFY102QFY103QFY104QFY101QFY112QFY113QFY114QFY111QFY122QFY123QFY124QFY121QFY132QFY133QFY134QFY131QFY142QFY143QFY144QFY141QFY152QFY15 RM cost (INR m)RM cost (% of rev)
29 October 2014 3 
Jagran Prakashan 
Consolidated quarterly performance 
2QFY14 
1QFY15 
2QFY15 
YoY (%) 
QoQ (%) 
2QFY15E 
v/s est (%) 
Advertising revenue 
2,842 
3,089 
3,069 
8.0 
-0.6 
3,069 
0.0 
Circulation revenue 
899 
957 
965 
7.3 
0.9 
992 
-2.7 
Others 
396 
357 
329 
-17.0 
-8.1 
400 
-17.9 
Revenue 
4,137 
4,403 
4,363 
5.4 
-0.9 
4,461 
-2.2 
Total operating cost 
3,219 
3,333 
3,300 
2.5 
-1.0 
3,418 
-3.4 
EBITDA 
918 
1,070 
1,062 
15.7 
-0.7 
1,044 
1.8 
EBITDA margin (%) 
22.2 
24.3 
24.4 
215bps 
4bps 
23.4 
96bps 
Depreciation 
190 
238 
245 
29.0 
3.1 
238 
3.1 
EBIT 
728 
832 
817 
12.2 
-1.8 
806 
1.4 
Interest 
78 
84 
73 
-6.3 
-12.3 
84 
-12.6 
Other Income incl sale of property 
-55 
69 
71 
-229.1 
3.2 
79 
-9.8 
PBT 
595 
818 
815 
37.1 
-0.3 
801 
1.8 
Tax 
139 
267 
249 
79.7 
NA 
261 
NA 
Tax rate (%) 
23 
33 
31 
724bps 
-209bps 
33 
-209bps 
Reported PAT 
456 
551 
566 
24.1 
2.8 
539 
4.9 
Operating expenses (INR m) 
Raw material 
1,473 
1,627 
1,603 
8.8 
-1.5 
1,578 
1.6 
Employee 
603 
648 
646 
7.3 
-0.2 
651 
-0.7 
Others 
1,143 
1,058 
1,051 
-8.0 
-0.6 
1,188 
-11.6 
Total 
3,219 
3,333 
3,300 
2.5 
-1.0 
3,418 
-3.4 
Opex (% of revenue) 
Raw material 
35.6 
37.0 
36.7 
113bps 
-21bps 
Employee 
14.6 
14.7 
14.8 
25bps 
10bps 
Others 
27.6 
24.0 
24.1 
-354bps 
7bps 
Source: Company, MOSL 
Summary of estimate change (INR b) 
FY15E 
FY16E 
FY17E 
Revenue 
Old 
18.52 
20.61 
22.51 
New 
18.32 
20.34 
22.16 
Change (%) 
-1.1 
-1.3 
-1.5 
EBITDA 
Old 
4.38 
5.06 
5.60 
New 
4.52 
5.15 
5.66 
Change (%) 
3.0 
1.9 
1.1 
EBITDA margin (%) 
Old 
23.7 
24.5 
24.9 
New 
24.6 
25.3 
25.5 
Change (bp) 
97 
80 
65 
Adj. PAT 
Old 
2.33 
2.89 
3.39 
New 
2.40 
2.96 
3.43 
Change (%) 
3.1 
2.3 
1.2 
Adj. EPS (INR) 
Old 
7.5 
9.3 
10.9 
New 
7.7 
9.5 
11.0 
Change (%) 
3.1 
2.3 
1.2 
Source: Company, MOSL
29 October 2014 4 
Jagran Prakashan 
Key assumptions & other data 
FY10 
FY11 
FY12 
FY13 
FY14 
FY15E 
FY16E 
FY17E 
Group ad revenue (INR b) 
6.4 
8.5 
9.4 
10.5 
11.9 
13.0 
14.5 
15.8 
YoY (%) 
16 
34 
10 
12 
13 
9 
12 
9 
-Standalone (exc. Nai Duniya) 
6.4 
7.7 
8.5 
8.9 
10.0 
11.0 
12.4 
13.5 
YoY (%) 
16 
20 
11 
4 
13 
10 
12 
9 
-Mid-Day + Inquilab 
0.8 
0.9 
0.9 
0.9 
0.9 
0.9 
1.0 
1.0 
YoY (%) 
4 
2 
-2 
5 
3 
3 
3 
-Nai Duniya 
0.8 
0.9 
1.0 
1.2 
1.3 
YoY (%) 
13 
16 
11 
13 
13 
Group circulation revenue (INR b) 
2.1 
2.4 
2.7 
3.2 
3.6 
3.9 
4.4 
4.9 
YoY (%) 
9 
12 
11 
20 
12 
9 
13 
11 
-Standalone (exc. Nai Duniya) 
2.1 
2.2 
2.4 
2.7 
3.1 
3.4 
3.8 
4.3 
YoY (%) 
10 
4 
10 
11 
13 
9 
13 
12 
-Mid-Day + Inquilab 
0.1 
0.2 
0.2 
0.2 
0.2 
0.2 
0.3 
0.3 
YoY (%) 
4 
28 
9 
5 
9 
9 
8 
-Nai Duniya 
0.3 
0.3 
0.3 
0.3 
0.3 
YoY (%) 
25 
10 
10 
10 
0 
Dainik Jagran av circulation/day (m) 
2.7 
3.0 
3.2 
3.5 
3.6 
3.9 
4.1 
4.3 
YoY (%) 
-2 
11 
8 
7 
4 
7 
7 
5 
Newsprint price (USD/ton) 
505 
573 
652 
610 
586 
600 
606 
611 
YoY (%) 
-20 
13 
14 
-6 
-4 
2 
1 
1 
RM cost/Revenue (%) 
29 
29 
34 
32 
32 
33 
33 
32 
Revenue mix (%) 
Ad revenue 
68 
70 
69 
69 
70 
71 
71 
71 
Circulation revenue 
23 
20 
20 
21 
21 
21 
22 
22 
Other 
10 
11 
11 
10 
9 
8 
7 
6 
Source: Company, MOSL
29 October 2014 5 
Jagran Prakashan 
Jagran Prakashan: an investment profile 
Company description 
Jagran Prakashan Ltd (JPL) is a leading media and communications group with its main interests across Newspaper, Outdoor, Internet, Magazine, Event Management and Short Code Sevice media, spanning across 11 states. JPL is a leading newspaper publisher. It's flagship brand Dainik Jagran has been the largest read and circulated newspaper in India. JPL has 3 newspaper titles - Dainik Jagran, I next and City Plus. Dainik Jagran is a Hindi newspaper printed out of 31 locations across 11 states, I next is a bilingual compact morning newspaper targeted at 18-35 yrs, SEC AB1 in key metros, while City Plus is a weekly English tabloid circulated in Gurgaon, Faridabad, Ghaziabad, Noida and Delhi. 
Key investment argument 
 Strong presence in tier II/III towns across the Hindi speaking belt 
 Footprint expansion led by Mid-Day and 'Nai Duniya' acquisitions 
 High dividend pay-out 
Key investment risks 
 High exposure to the UP print market 
 Increased competition in UP and Bihar markets 
Recent developments 
 Jagran’s board approved a final dividend of INR3/sh. 
Valuation and view 
 We are upgrading PAT estimates by 1-3% on higher margin assumptions. We expect proforma EPS CAGR of 19% over FY14-17E driven by 10% ad revenue CAGR and EBITDA margin expansion of ~310 bps. 
 The stock trades at P/E of 16.5x FY15E and 13.4x FY16E. Maintain Buy with a price target of INR165 based on 16x average FY16/17 EPS. 
Comparative valuations 
Jagran HT Media DB Corp 
P/E (x) FY15E 16.6 13.3 18.3 
FY16E 13.5 11.7 15.5 
EV/EBITDA (x) FY15E 9.1 5.5 10.3 
FY16E 7.7 4.2 8.7 
Div. Yield (%) FY15E 3.1 0.3 2.4 
FY16E 3.1 0.4 2.9 
P/BV (x) FY15E 3.8 1.2 5.0 
FY16E 3.3 1.1 4.3 
EPS: MOSL forecast v/s consensus (INR) 
MOSL Consensus Variation 
Forecast Forecast (%) 
FY15 7.7 8.1 -5.4 
FY16 9.5 9.8 -3.0 
Target price and recommendation 
Current Target Upside Reco. 
Price (INR) Price (INR) (%) 
127 165 29.9 Buy 
Shareholding pattern (%) 
Jun-14 Mar-14 Jun-13 
Promoter 62.6 62.6 61.6 
DII 9.5 9.1 12.3 
FII 15.1 14.0 12.7 
Others 12.8 14.4 13.3 
Note: FII Includes depository receipts 
Stock performance (1-year) 
7593111129147Oct-13Jan-14Apr-14Jul-14Oct-14Jagran PrakashanSensex -Rebased
29 October 2014 6 
Jagran Prakashan 
Financials and valuation 
Income Statement (Consolidated)(INR Million) Y/E March20142015E2016E2017ENet Sales 17,02718,32320,33722,163YoY (%)11.67.611.09.0EBITDA3,8264,5165,1535,660EBITDA margin (%)22.524.625.325.5Depreciation789974928925Interest345335326326Other Income117359492684PBT2,8103,5654,3905,092Tax7951,1641,4331,662Tax rate (%)28.332.632.632.6Adjusted PAT2,0152,4012,9573,430 Change (%)36.619.223.216.0Extra-ordinary items248000Reported PAT2,2632,4012,9573,430Balance SheetY/E March20142015E2016E2017EShare Capital623623623623Share Premium3,1253,1253,1253,125Reserves5,8696,8138,31410,287Net Worth9,61610,56112,06114,034Loans4,6584,6584,6584,658Deffered Tax Liability854854854854Minority interest9999Capital Employed 15,13716,08217,58219,555Gross Fixed Assets11,23211,96512,77813,665Less: Depreciation4,8235,7976,7257,651Net Fixed Assets6,4096,1676,0536,014Capital WIP316316316316Goodwill2,3232,3232,3232,323Investments3,3203,3203,3203,320Curr. Assets6,8888,38710,48912,943Inventory9991,0901,1911,281Debtors3,4263,7654,1794,554Cash & Bank Balance3251,2312,5664,326Loans & Advances1,4651,5771,7501,907Other current assets673724803875Current Liab. & Prov.4,1194,4324,9195,361Creditors2,8793,0983,4383,747Provisions & other liabilitie1,2401,3351,4811,614Net Current Assets 2,7693,9555,5707,582Application of Funds15,13716,08217,58219,555E: MOSL EstimatesRatiosY/E March20142015E2016E2017EBasic (INR) Adjusted EPS 6.47.79.511.0Growth (%)37.720.123.216.0Cash EPS 8.910.812.514.0Book Value30.734.038.845.1DPS4.04.04.04.0Payout (incl. Div. Tax.) (%)72614942ValuationP/E 19.816.513.411.5Cash P/E14.211.710.29.1EV/EBITDA10.99.17.76.7EV/Sales2.52.21.91.7Price/Book Value4.13.73.32.8Dividend Yield (%)3.13.13.13.1Profitability Ratios (%) RoE21.323.826.126.3RoCE 16.716.818.819.6Turnover RatiosDebtors (Days)73757575Inventory (Days)21222121Creditors. (Days)80828383Asset Turnover (x)1.51.61.81.9Leverage RatioDebt/Equity (x)0.50.40.40.3Cash Flow Statement(INR Million) Y/E March20142015E2016E2017EOp.Profit/(Loss) bef Tax3,8264,5165,1535,660Other Income117359492684Interest Paid-345-335-326-326Direct Taxes Paid-795-1,164-1,433-1,662(Inc)/Dec in Wkg. Cap.372-280-280-253CF from Op.Activity3,1763,0963,6054,102(inc)/Dec in FA + CWIP-768-733-813-887(Pur)/Sale of Investments-1,096000CF from Inv.Activity-1,864-733-813-887Inc/(Dec) in Debt35000Dividends Paid-1,457-1,457-1,457-1,457Other Financing Activities-2000CF from Fin.Activity-1,899-1,457-1,457-1,457Inc/(Dec) in Cash-5889061,3351,759Add: Opening Balance5233251,2312,566Closing Balance3251,2312,5664,326
29 October 2014 7 
Jagran Prakashan 
N O T E S
29 October 2014 8 
Jagran Prakashan 
Disclosures 
This research report has been prepared by MOSt to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its affiliated company(ies). This report is for personal information of the select recipient and does not construe to be any investment, legal or taxation advice to you. This research report does not constitute an offer, invitation or inducement to invest in securities or other investments and Motilal Oswal Securities Limited (hereinafter referred as MOSt) is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your general information and should not be reproduced or redistributed to any other person in any form. This report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, investors should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. 
MOSt and its affiliates are a full-service, integrated investment banking, investment management, brokerage and financing group. We and our affiliates have investment banking and other business relationships with a significant percentage of the companies covered by our Research Department Our research professionals provide important input into our investment banking and other business selection processes. Investors should assume that MOSt and/or its affiliates are seeking or will seek investment banking or other business from the company or companies that are the subject of this material and that the research professionals who were involved in preparing this material may participate in the solicitation of such business. The research professionals responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting market information. Our research professionals are paid in part based on the profitability of MOSt which include earnings from investment banking and other business. MOSt generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, MOSt generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover. Our salespeople, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all o the foregoing, among other things, may give rise to real or potential conflicts of interest . MOSt and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. 
Unauthorized disclosure, use, dissemination or copying (either whole or partial) of this information, is prohibited. The person accessing this information specifically agrees to exempt MOSt or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOSt or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOSt or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays. The information contained herein is based on publicly available data or other sources believed to be reliable. Any statements contained in this report attributed to a third party represent MOSt’s interpretation of the data, information and/or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party. This Report is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. While we would endeavor to update the information herein on reasonable basis, MOSt and/or its affiliates are under no obligation to update the information. Also there may be regulatory, compliance, or other reasons that may prevent MOSt and/or its affiliates from doing so. MOSt or any of its affiliates or employees shall not be in any way responsible and liable for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. MOSt or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations. 
Recipients who are not institutional investors should seek advice of their independent financial advisor prior to taking any investment decision based on this report or for any necessary explanation of its contents. 
MOSt and/or its affiliates and/or employees may have interests/positions, financial or otherwise in the securities mentioned in this report. To enhance transparency, MOSt has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. 
Disclosure of Interest Statement JAGRAN PRAKASHAN LTD 
 Analyst ownership of the stock No 
Analyst Certification 
The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The research analysts, strategists, or research associates principally responsible for preparation of MOSt research receive compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues. 
Regional Disclosures (outside India) 
This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOSt & its group companies to registration or licensing requirements within such jurisdictions. 
For U.K. 
This report is intended for distribution only to persons having professional experience in matters relating to investments as described in Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (referred to as "investment professionals"). This document must not be acted on or relied on by persons who are not investment professionals. Any investment or investment activity to which this document relates is only available to investment professionals and will be engaged in only with such persons. 
For U.S. 
Motilal Oswal Securities Limited (MOSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition MOSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOSL, including the products and services described herein are not available to or intended for U.S. persons. 
This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement. 
The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account. 
For Singapore 
Motilal Oswal Capital Markets Singapore Pte Limited is acting as an exempt financial advisor under section 23(1)(f) of the Financial Advisers Act(FAA) read with regulation 17(1)(d) of the Financial Advisors Regulations and is a subsidiary of Motilal Oswal Securities Limited in India. This research is distributed in Singapore by Motilal Oswal Capital Markets Singapore Pte Limited and it is only directed in Singapore to accredited investors, as defined in the Financial Advisers Regulations and the Securities and Futures Act (Chapter 289), as amended from time to time. 
In respect of any matter arising from or in connection with the research you could contact the following representatives of Motilal Oswal Capital Markets Singapore Pte Limited: 
Anosh Koppikar Kadambari Balachandran 
Email : anosh.Koppikar@motilaloswal.com Email : kadambari.balachandran@motilaloswal.com 
Contact : (+65)68189232 Contact : (+65) 68189233 / 65249115 
Office Address : 21 (Suite 31),16 Collyer Quay,Singapore 04931 
Motilal Oswal Securities Ltd 
Motilal Oswal Tower, Level 9, Sayani Road, Prabhadevi, Mumbai 400 025 
Phone: +91 22 3982 5500 E-mail: reports@motilaloswal.com

More Related Content

What's hot

2006 10-02 Q4 & Full Year 2005/2006 Results
2006 10-02 Q4 & Full Year 2005/2006 Results2006 10-02 Q4 & Full Year 2005/2006 Results
2006 10-02 Q4 & Full Year 2005/2006 ResultsKappAhl
 
Cipla result update 4 qfy2010 100510
Cipla result update 4 qfy2010 100510Cipla result update 4 qfy2010 100510
Cipla result update 4 qfy2010 100510guest45ce0f1
 
Itc ru4 qfy2010-22-05-10
Itc ru4 qfy2010-22-05-10Itc ru4 qfy2010-22-05-10
Itc ru4 qfy2010-22-05-10Angel Broking
 
northrop grumman Q406 and Year-End 2006 Earnings Announcement
northrop grumman Q406 and Year-End 2006 Earnings Announcementnorthrop grumman Q406 and Year-End 2006 Earnings Announcement
northrop grumman Q406 and Year-End 2006 Earnings Announcementfinance8
 
Alembic Pharma Ltd: Stock Price & Q4 Results Of Alembic Pharma | HDFC securities
Alembic Pharma Ltd: Stock Price & Q4 Results Of Alembic Pharma | HDFC securitiesAlembic Pharma Ltd: Stock Price & Q4 Results Of Alembic Pharma | HDFC securities
Alembic Pharma Ltd: Stock Price & Q4 Results Of Alembic Pharma | HDFC securitieshdfcsecurities1
 
Q2 2017 Investor Presentation
Q2 2017 Investor PresentationQ2 2017 Investor Presentation
Q2 2017 Investor PresentationNEXONIR
 
Marico ru2 qfy2011-261010
Marico ru2 qfy2011-261010Marico ru2 qfy2011-261010
Marico ru2 qfy2011-261010Angel Broking
 
2006 Analystsand Investors Meeting
2006 Analystsand Investors Meeting2006 Analystsand Investors Meeting
2006 Analystsand Investors MeetingLocaliza
 
Nestle Result Update
Nestle  Result UpdateNestle  Result Update
Nestle Result UpdateAngel Broking
 
Aventis Result Update
Aventis Result UpdateAventis Result Update
Aventis Result UpdateAngel Broking
 
M&m ru2 qfy2011-291010
M&m ru2 qfy2011-291010M&m ru2 qfy2011-291010
M&m ru2 qfy2011-291010Angel Broking
 
Fce deepak nitrite_28jul15
Fce deepak nitrite_28jul15Fce deepak nitrite_28jul15
Fce deepak nitrite_28jul15IndiaNotes.com
 
Fag bearing ru3 qcy2010-221010
Fag bearing ru3 qcy2010-221010Fag bearing ru3 qcy2010-221010
Fag bearing ru3 qcy2010-221010Angel Broking
 
Finolex cables ru2 qfy2011-251010
Finolex cables ru2 qfy2011-251010Finolex cables ru2 qfy2011-251010
Finolex cables ru2 qfy2011-251010Angel Broking
 
Procter & Gamble Analysis
Procter & Gamble AnalysisProcter & Gamble Analysis
Procter & Gamble AnalysisDavid Hatfield
 
Sun tv ru2 qfy2011-291010
Sun tv  ru2 qfy2011-291010Sun tv  ru2 qfy2011-291010
Sun tv ru2 qfy2011-291010Angel Broking
 
Colgate ru2 qfy2011-281010
Colgate  ru2 qfy2011-281010Colgate  ru2 qfy2011-281010
Colgate ru2 qfy2011-281010Angel Broking
 
Firstcall fineotex chemical_ltd_2_july15
Firstcall fineotex chemical_ltd_2_july15Firstcall fineotex chemical_ltd_2_july15
Firstcall fineotex chemical_ltd_2_july15IndiaNotes.com
 

What's hot (20)

2006 10-02 Q4 & Full Year 2005/2006 Results
2006 10-02 Q4 & Full Year 2005/2006 Results2006 10-02 Q4 & Full Year 2005/2006 Results
2006 10-02 Q4 & Full Year 2005/2006 Results
 
Cipla result update 4 qfy2010 100510
Cipla result update 4 qfy2010 100510Cipla result update 4 qfy2010 100510
Cipla result update 4 qfy2010 100510
 
Itc ru4 qfy2010-22-05-10
Itc ru4 qfy2010-22-05-10Itc ru4 qfy2010-22-05-10
Itc ru4 qfy2010-22-05-10
 
northrop grumman Q406 and Year-End 2006 Earnings Announcement
northrop grumman Q406 and Year-End 2006 Earnings Announcementnorthrop grumman Q406 and Year-End 2006 Earnings Announcement
northrop grumman Q406 and Year-End 2006 Earnings Announcement
 
Alembic Pharma Ltd: Stock Price & Q4 Results Of Alembic Pharma | HDFC securities
Alembic Pharma Ltd: Stock Price & Q4 Results Of Alembic Pharma | HDFC securitiesAlembic Pharma Ltd: Stock Price & Q4 Results Of Alembic Pharma | HDFC securities
Alembic Pharma Ltd: Stock Price & Q4 Results Of Alembic Pharma | HDFC securities
 
Analyst presentation q2 2018 v13
Analyst presentation   q2 2018 v13Analyst presentation   q2 2018 v13
Analyst presentation q2 2018 v13
 
Q2 2017 Investor Presentation
Q2 2017 Investor PresentationQ2 2017 Investor Presentation
Q2 2017 Investor Presentation
 
Marico ru2 qfy2011-261010
Marico ru2 qfy2011-261010Marico ru2 qfy2011-261010
Marico ru2 qfy2011-261010
 
2006 Analystsand Investors Meeting
2006 Analystsand Investors Meeting2006 Analystsand Investors Meeting
2006 Analystsand Investors Meeting
 
Nestle Result Update
Nestle  Result UpdateNestle  Result Update
Nestle Result Update
 
Aventis Result Update
Aventis Result UpdateAventis Result Update
Aventis Result Update
 
M&m ru2 qfy2011-291010
M&m ru2 qfy2011-291010M&m ru2 qfy2011-291010
M&m ru2 qfy2011-291010
 
Fce deepak nitrite_28jul15
Fce deepak nitrite_28jul15Fce deepak nitrite_28jul15
Fce deepak nitrite_28jul15
 
Fag bearing ru3 qcy2010-221010
Fag bearing ru3 qcy2010-221010Fag bearing ru3 qcy2010-221010
Fag bearing ru3 qcy2010-221010
 
Finolex cables ru2 qfy2011-251010
Finolex cables ru2 qfy2011-251010Finolex cables ru2 qfy2011-251010
Finolex cables ru2 qfy2011-251010
 
Procter & Gamble Analysis
Procter & Gamble AnalysisProcter & Gamble Analysis
Procter & Gamble Analysis
 
Sun tv ru2 qfy2011-291010
Sun tv  ru2 qfy2011-291010Sun tv  ru2 qfy2011-291010
Sun tv ru2 qfy2011-291010
 
Colgate ru2 qfy2011-281010
Colgate  ru2 qfy2011-281010Colgate  ru2 qfy2011-281010
Colgate ru2 qfy2011-281010
 
Q1 2009 Earning Report of Alcon Inc.
Q1 2009 Earning Report of Alcon Inc.Q1 2009 Earning Report of Alcon Inc.
Q1 2009 Earning Report of Alcon Inc.
 
Firstcall fineotex chemical_ltd_2_july15
Firstcall fineotex chemical_ltd_2_july15Firstcall fineotex chemical_ltd_2_july15
Firstcall fineotex chemical_ltd_2_july15
 

Viewers also liked

Viewers also liked (7)

FgmBizPlanDraft
FgmBizPlanDraftFgmBizPlanDraft
FgmBizPlanDraft
 
OSC2011 Tokyo/Fall JOSUG
OSC2011 Tokyo/Fall JOSUGOSC2011 Tokyo/Fall JOSUG
OSC2011 Tokyo/Fall JOSUG
 
проект
проектпроект
проект
 
Blog blogger
Blog bloggerBlog blogger
Blog blogger
 
Bord Gáis Energy Index June 2015
Bord Gáis Energy Index June 2015Bord Gáis Energy Index June 2015
Bord Gáis Energy Index June 2015
 
Criando Blog no Blogger
Criando Blog no BloggerCriando Blog no Blogger
Criando Blog no Blogger
 
соколова о. славсько 12
соколова о. славсько 12соколова о. славсько 12
соколова о. славсько 12
 

Similar to Jagran 2QFY15 Results Update Indicates Revenue and Profit Growth

Jagran Prakashan Q1FY15: Buy
 Jagran Prakashan Q1FY15: Buy Jagran Prakashan Q1FY15: Buy
Jagran Prakashan Q1FY15: BuyIndiaNotes.com
 
Buy DB Corp at a target of Rs410
Buy DB Corp at a target of Rs410Buy DB Corp at a target of Rs410
Buy DB Corp at a target of Rs410IndiaNotes.com
 
Vaibhav Global Q1FY15: Outlook continues to remain positive; Hold
 Vaibhav Global Q1FY15: Outlook continues to remain positive; Hold Vaibhav Global Q1FY15: Outlook continues to remain positive; Hold
Vaibhav Global Q1FY15: Outlook continues to remain positive; HoldIndiaNotes.com
 
Mahindra Financial result update: 4QFY15 PAT up 7% YoY and 144% QoQ
Mahindra Financial result update: 4QFY15 PAT up 7% YoY and 144% QoQMahindra Financial result update: 4QFY15 PAT up 7% YoY and 144% QoQ
Mahindra Financial result update: 4QFY15 PAT up 7% YoY and 144% QoQIndiaNotes.com
 
Britannia Industries 1QFY15 results ahead of estimate; buy - Motilal Oswal
Britannia Industries 1QFY15 results ahead of estimate; buy - Motilal OswalBritannia Industries 1QFY15 results ahead of estimate; buy - Motilal Oswal
Britannia Industries 1QFY15 results ahead of estimate; buy - Motilal OswalIndiaNotes.com
 
Bayer india ru4qfy2010-020610
Bayer india ru4qfy2010-020610Bayer india ru4qfy2010-020610
Bayer india ru4qfy2010-020610Angel Broking
 
Godrej Consumer's Q4 results were slightly below expectations; Neutral
Godrej Consumer's Q4 results were slightly below expectations; NeutralGodrej Consumer's Q4 results were slightly below expectations; Neutral
Godrej Consumer's Q4 results were slightly below expectations; NeutralIndiaNotes.com
 
ENIL 1QFY18
ENIL 1QFY18ENIL 1QFY18
ENIL 1QFY18Mohit Jn
 
Idea Cellular Q4FY15: PAT up 60% y-o-y; rating Under Review
Idea Cellular Q4FY15: PAT up 60% y-o-y; rating Under ReviewIdea Cellular Q4FY15: PAT up 60% y-o-y; rating Under Review
Idea Cellular Q4FY15: PAT up 60% y-o-y; rating Under ReviewIndiaNotes.com
 
Prabhudas lilladher techmahindra_29june_2015
Prabhudas lilladher techmahindra_29june_2015Prabhudas lilladher techmahindra_29june_2015
Prabhudas lilladher techmahindra_29june_2015IndiaNotes.com
 
Dabur Q3FY15: Mixed quarter; maintain neutral
 Dabur Q3FY15: Mixed quarter; maintain neutral Dabur Q3FY15: Mixed quarter; maintain neutral
Dabur Q3FY15: Mixed quarter; maintain neutralIndiaNotes.com
 
Q2FY15: Hold Mahindra & Mahindra Financial Services - Nirmal Bang
Q2FY15: Hold Mahindra & Mahindra Financial Services - Nirmal BangQ2FY15: Hold Mahindra & Mahindra Financial Services - Nirmal Bang
Q2FY15: Hold Mahindra & Mahindra Financial Services - Nirmal BangIndiaNotes.com
 
Intrasoft 1QFY18
Intrasoft 1QFY18Intrasoft 1QFY18
Intrasoft 1QFY18Mohit Jn
 
Sun TV Q1FY15 adjusted PAT increases 5% YoY; buy - buy - Motilal Oswal
Sun TV Q1FY15 adjusted PAT increases 5% YoY; buy - buy - Motilal OswalSun TV Q1FY15 adjusted PAT increases 5% YoY; buy - buy - Motilal Oswal
Sun TV Q1FY15 adjusted PAT increases 5% YoY; buy - buy - Motilal OswalIndiaNotes.com
 
Jagran prakashan ru4 qfy2010-270510
Jagran prakashan ru4 qfy2010-270510Jagran prakashan ru4 qfy2010-270510
Jagran prakashan ru4 qfy2010-270510Angel Broking
 
ITC 1QFY15 results largely in-line; buy
 ITC 1QFY15 results largely in-line; buy ITC 1QFY15 results largely in-line; buy
ITC 1QFY15 results largely in-line; buyIndiaNotes.com
 
Yes Bank: Reports tepid set of numbers in Q1FY15; Hold
 Yes Bank: Reports tepid set of numbers in Q1FY15; Hold Yes Bank: Reports tepid set of numbers in Q1FY15; Hold
Yes Bank: Reports tepid set of numbers in Q1FY15; HoldIndiaNotes.com
 
Zydus Wellness reports a subdued quarter, hold - Nirmal Bang
Zydus Wellness reports a subdued quarter, hold - Nirmal BangZydus Wellness reports a subdued quarter, hold - Nirmal Bang
Zydus Wellness reports a subdued quarter, hold - Nirmal BangIndiaNotes.com
 
20160502 olympus pres
20160502 olympus pres20160502 olympus pres
20160502 olympus presTravis Lundy
 
Motilal oswal dishtv_30oct_2014
Motilal oswal dishtv_30oct_2014Motilal oswal dishtv_30oct_2014
Motilal oswal dishtv_30oct_2014IndiaNotes.com
 

Similar to Jagran 2QFY15 Results Update Indicates Revenue and Profit Growth (20)

Jagran Prakashan Q1FY15: Buy
 Jagran Prakashan Q1FY15: Buy Jagran Prakashan Q1FY15: Buy
Jagran Prakashan Q1FY15: Buy
 
Buy DB Corp at a target of Rs410
Buy DB Corp at a target of Rs410Buy DB Corp at a target of Rs410
Buy DB Corp at a target of Rs410
 
Vaibhav Global Q1FY15: Outlook continues to remain positive; Hold
 Vaibhav Global Q1FY15: Outlook continues to remain positive; Hold Vaibhav Global Q1FY15: Outlook continues to remain positive; Hold
Vaibhav Global Q1FY15: Outlook continues to remain positive; Hold
 
Mahindra Financial result update: 4QFY15 PAT up 7% YoY and 144% QoQ
Mahindra Financial result update: 4QFY15 PAT up 7% YoY and 144% QoQMahindra Financial result update: 4QFY15 PAT up 7% YoY and 144% QoQ
Mahindra Financial result update: 4QFY15 PAT up 7% YoY and 144% QoQ
 
Britannia Industries 1QFY15 results ahead of estimate; buy - Motilal Oswal
Britannia Industries 1QFY15 results ahead of estimate; buy - Motilal OswalBritannia Industries 1QFY15 results ahead of estimate; buy - Motilal Oswal
Britannia Industries 1QFY15 results ahead of estimate; buy - Motilal Oswal
 
Bayer india ru4qfy2010-020610
Bayer india ru4qfy2010-020610Bayer india ru4qfy2010-020610
Bayer india ru4qfy2010-020610
 
Godrej Consumer's Q4 results were slightly below expectations; Neutral
Godrej Consumer's Q4 results were slightly below expectations; NeutralGodrej Consumer's Q4 results were slightly below expectations; Neutral
Godrej Consumer's Q4 results were slightly below expectations; Neutral
 
ENIL 1QFY18
ENIL 1QFY18ENIL 1QFY18
ENIL 1QFY18
 
Idea Cellular Q4FY15: PAT up 60% y-o-y; rating Under Review
Idea Cellular Q4FY15: PAT up 60% y-o-y; rating Under ReviewIdea Cellular Q4FY15: PAT up 60% y-o-y; rating Under Review
Idea Cellular Q4FY15: PAT up 60% y-o-y; rating Under Review
 
Prabhudas lilladher techmahindra_29june_2015
Prabhudas lilladher techmahindra_29june_2015Prabhudas lilladher techmahindra_29june_2015
Prabhudas lilladher techmahindra_29june_2015
 
Dabur Q3FY15: Mixed quarter; maintain neutral
 Dabur Q3FY15: Mixed quarter; maintain neutral Dabur Q3FY15: Mixed quarter; maintain neutral
Dabur Q3FY15: Mixed quarter; maintain neutral
 
Q2FY15: Hold Mahindra & Mahindra Financial Services - Nirmal Bang
Q2FY15: Hold Mahindra & Mahindra Financial Services - Nirmal BangQ2FY15: Hold Mahindra & Mahindra Financial Services - Nirmal Bang
Q2FY15: Hold Mahindra & Mahindra Financial Services - Nirmal Bang
 
Intrasoft 1QFY18
Intrasoft 1QFY18Intrasoft 1QFY18
Intrasoft 1QFY18
 
Sun TV Q1FY15 adjusted PAT increases 5% YoY; buy - buy - Motilal Oswal
Sun TV Q1FY15 adjusted PAT increases 5% YoY; buy - buy - Motilal OswalSun TV Q1FY15 adjusted PAT increases 5% YoY; buy - buy - Motilal Oswal
Sun TV Q1FY15 adjusted PAT increases 5% YoY; buy - buy - Motilal Oswal
 
Jagran prakashan ru4 qfy2010-270510
Jagran prakashan ru4 qfy2010-270510Jagran prakashan ru4 qfy2010-270510
Jagran prakashan ru4 qfy2010-270510
 
ITC 1QFY15 results largely in-line; buy
 ITC 1QFY15 results largely in-line; buy ITC 1QFY15 results largely in-line; buy
ITC 1QFY15 results largely in-line; buy
 
Yes Bank: Reports tepid set of numbers in Q1FY15; Hold
 Yes Bank: Reports tepid set of numbers in Q1FY15; Hold Yes Bank: Reports tepid set of numbers in Q1FY15; Hold
Yes Bank: Reports tepid set of numbers in Q1FY15; Hold
 
Zydus Wellness reports a subdued quarter, hold - Nirmal Bang
Zydus Wellness reports a subdued quarter, hold - Nirmal BangZydus Wellness reports a subdued quarter, hold - Nirmal Bang
Zydus Wellness reports a subdued quarter, hold - Nirmal Bang
 
20160502 olympus pres
20160502 olympus pres20160502 olympus pres
20160502 olympus pres
 
Motilal oswal dishtv_30oct_2014
Motilal oswal dishtv_30oct_2014Motilal oswal dishtv_30oct_2014
Motilal oswal dishtv_30oct_2014
 

More from IndiaNotes.com

Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15IndiaNotes.com
 
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaIndiaNotes.com
 
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaIndiaNotes.com
 
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccinesHester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccinesIndiaNotes.com
 
Vidhi Dyestuffs: To keep its growth story in the coming quarters also
Vidhi Dyestuffs: To keep its growth story in the coming quarters alsoVidhi Dyestuffs: To keep its growth story in the coming quarters also
Vidhi Dyestuffs: To keep its growth story in the coming quarters alsoIndiaNotes.com
 
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacityApollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacityIndiaNotes.com
 
Grasim Industries reports improved performance in Q1FY16
Grasim Industries reports improved performance in Q1FY16Grasim Industries reports improved performance in Q1FY16
Grasim Industries reports improved performance in Q1FY16IndiaNotes.com
 
Cummins India: No interest burden being free from long-term or short-term debt
Cummins India: No interest burden being free from long-term or short-term debtCummins India: No interest burden being free from long-term or short-term debt
Cummins India: No interest burden being free from long-term or short-term debtIndiaNotes.com
 
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...IndiaNotes.com
 
Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...IndiaNotes.com
 
Capital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CARECapital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CAREIndiaNotes.com
 
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...IndiaNotes.com
 
Canara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16ECanara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16EIndiaNotes.com
 
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...IndiaNotes.com
 
Hexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, BuyHexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, BuyIndiaNotes.com
 
Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15IndiaNotes.com
 
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; HoldIndoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; HoldIndiaNotes.com
 
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; BuyPI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; BuyIndiaNotes.com
 

More from IndiaNotes.com (20)

Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15
 
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
 
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
 
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccinesHester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccines
 
Vidhi Dyestuffs: To keep its growth story in the coming quarters also
Vidhi Dyestuffs: To keep its growth story in the coming quarters alsoVidhi Dyestuffs: To keep its growth story in the coming quarters also
Vidhi Dyestuffs: To keep its growth story in the coming quarters also
 
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacityApollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
 
Grasim Industries reports improved performance in Q1FY16
Grasim Industries reports improved performance in Q1FY16Grasim Industries reports improved performance in Q1FY16
Grasim Industries reports improved performance in Q1FY16
 
Cummins India: No interest burden being free from long-term or short-term debt
Cummins India: No interest burden being free from long-term or short-term debtCummins India: No interest burden being free from long-term or short-term debt
Cummins India: No interest burden being free from long-term or short-term debt
 
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
 
Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...
 
Capital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CARECapital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CARE
 
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
 
Canara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16ECanara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16E
 
Nirmal lupin 06_aug15
Nirmal lupin 06_aug15Nirmal lupin 06_aug15
Nirmal lupin 06_aug15
 
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
 
Hexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, BuyHexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, Buy
 
Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15
 
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; HoldIndoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
 
Fce thermax 31_jul15
Fce thermax 31_jul15Fce thermax 31_jul15
Fce thermax 31_jul15
 
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; BuyPI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
 

Recently uploaded

(办理学位证)加拿大萨省大学毕业证成绩单原版一比一
(办理学位证)加拿大萨省大学毕业证成绩单原版一比一(办理学位证)加拿大萨省大学毕业证成绩单原版一比一
(办理学位证)加拿大萨省大学毕业证成绩单原版一比一S SDS
 
原版1:1复刻温哥华岛大学毕业证Vancouver毕业证留信学历认证
原版1:1复刻温哥华岛大学毕业证Vancouver毕业证留信学历认证原版1:1复刻温哥华岛大学毕业证Vancouver毕业证留信学历认证
原版1:1复刻温哥华岛大学毕业证Vancouver毕业证留信学历认证rjrjkk
 
Call Girls Near Me WhatsApp:+91-9833363713
Call Girls Near Me WhatsApp:+91-9833363713Call Girls Near Me WhatsApp:+91-9833363713
Call Girls Near Me WhatsApp:+91-9833363713Sonam Pathan
 
Vp Girls near me Delhi Call Now or WhatsApp
Vp Girls near me Delhi Call Now or WhatsAppVp Girls near me Delhi Call Now or WhatsApp
Vp Girls near me Delhi Call Now or WhatsAppmiss dipika
 
Call Girls Near Delhi Pride Hotel, New Delhi|9873777170
Call Girls Near Delhi Pride Hotel, New Delhi|9873777170Call Girls Near Delhi Pride Hotel, New Delhi|9873777170
Call Girls Near Delhi Pride Hotel, New Delhi|9873777170Sonam Pathan
 
(办理学位证)美国加州州立大学东湾分校毕业证成绩单原版一比一
(办理学位证)美国加州州立大学东湾分校毕业证成绩单原版一比一(办理学位证)美国加州州立大学东湾分校毕业证成绩单原版一比一
(办理学位证)美国加州州立大学东湾分校毕业证成绩单原版一比一S SDS
 
Tenets of Physiocracy History of Economic
Tenets of Physiocracy History of EconomicTenets of Physiocracy History of Economic
Tenets of Physiocracy History of Economiccinemoviesu
 
Stock Market Brief Deck for "this does not happen often".pdf
Stock Market Brief Deck for "this does not happen often".pdfStock Market Brief Deck for "this does not happen often".pdf
Stock Market Brief Deck for "this does not happen often".pdfMichael Silva
 
《加拿大本地办假证-寻找办理Dalhousie毕业证和达尔豪斯大学毕业证书的中介代理》
《加拿大本地办假证-寻找办理Dalhousie毕业证和达尔豪斯大学毕业证书的中介代理》《加拿大本地办假证-寻找办理Dalhousie毕业证和达尔豪斯大学毕业证书的中介代理》
《加拿大本地办假证-寻找办理Dalhousie毕业证和达尔豪斯大学毕业证书的中介代理》rnrncn29
 
call girls in Nand Nagri (DELHI) 🔝 >༒9953330565🔝 genuine Escort Service 🔝✔️✔️
call girls in  Nand Nagri (DELHI) 🔝 >༒9953330565🔝 genuine Escort Service 🔝✔️✔️call girls in  Nand Nagri (DELHI) 🔝 >༒9953330565🔝 genuine Escort Service 🔝✔️✔️
call girls in Nand Nagri (DELHI) 🔝 >༒9953330565🔝 genuine Escort Service 🔝✔️✔️9953056974 Low Rate Call Girls In Saket, Delhi NCR
 
House of Commons ; CDC schemes overview document
House of Commons ; CDC schemes overview documentHouse of Commons ; CDC schemes overview document
House of Commons ; CDC schemes overview documentHenry Tapper
 
Bladex 1Q24 Earning Results Presentation
Bladex 1Q24 Earning Results PresentationBladex 1Q24 Earning Results Presentation
Bladex 1Q24 Earning Results PresentationBladex
 
212MTAMount Durham University Bachelor's Diploma in Technology
212MTAMount Durham University Bachelor's Diploma in Technology212MTAMount Durham University Bachelor's Diploma in Technology
212MTAMount Durham University Bachelor's Diploma in Technologyz xss
 
SBP-Market-Operations and market managment
SBP-Market-Operations and market managmentSBP-Market-Operations and market managment
SBP-Market-Operations and market managmentfactical
 
Economic Risk Factor Update: April 2024 [SlideShare]
Economic Risk Factor Update: April 2024 [SlideShare]Economic Risk Factor Update: April 2024 [SlideShare]
Economic Risk Factor Update: April 2024 [SlideShare]Commonwealth
 
magnetic-pensions-a-new-blueprint-for-the-dc-landscape.pdf
magnetic-pensions-a-new-blueprint-for-the-dc-landscape.pdfmagnetic-pensions-a-new-blueprint-for-the-dc-landscape.pdf
magnetic-pensions-a-new-blueprint-for-the-dc-landscape.pdfHenry Tapper
 
NO1 Certified Amil Baba In Lahore Kala Jadu In Lahore Best Amil In Lahore Ami...
NO1 Certified Amil Baba In Lahore Kala Jadu In Lahore Best Amil In Lahore Ami...NO1 Certified Amil Baba In Lahore Kala Jadu In Lahore Best Amil In Lahore Ami...
NO1 Certified Amil Baba In Lahore Kala Jadu In Lahore Best Amil In Lahore Ami...Amil baba
 
(办理原版一样)QUT毕业证昆士兰科技大学毕业证学位证留信学历认证成绩单补办
(办理原版一样)QUT毕业证昆士兰科技大学毕业证学位证留信学历认证成绩单补办(办理原版一样)QUT毕业证昆士兰科技大学毕业证学位证留信学历认证成绩单补办
(办理原版一样)QUT毕业证昆士兰科技大学毕业证学位证留信学历认证成绩单补办fqiuho152
 
government_intervention_in_business_ownership[1].pdf
government_intervention_in_business_ownership[1].pdfgovernment_intervention_in_business_ownership[1].pdf
government_intervention_in_business_ownership[1].pdfshaunmashale756
 

Recently uploaded (20)

(办理学位证)加拿大萨省大学毕业证成绩单原版一比一
(办理学位证)加拿大萨省大学毕业证成绩单原版一比一(办理学位证)加拿大萨省大学毕业证成绩单原版一比一
(办理学位证)加拿大萨省大学毕业证成绩单原版一比一
 
原版1:1复刻温哥华岛大学毕业证Vancouver毕业证留信学历认证
原版1:1复刻温哥华岛大学毕业证Vancouver毕业证留信学历认证原版1:1复刻温哥华岛大学毕业证Vancouver毕业证留信学历认证
原版1:1复刻温哥华岛大学毕业证Vancouver毕业证留信学历认证
 
Call Girls Near Me WhatsApp:+91-9833363713
Call Girls Near Me WhatsApp:+91-9833363713Call Girls Near Me WhatsApp:+91-9833363713
Call Girls Near Me WhatsApp:+91-9833363713
 
Vp Girls near me Delhi Call Now or WhatsApp
Vp Girls near me Delhi Call Now or WhatsAppVp Girls near me Delhi Call Now or WhatsApp
Vp Girls near me Delhi Call Now or WhatsApp
 
Call Girls Near Delhi Pride Hotel, New Delhi|9873777170
Call Girls Near Delhi Pride Hotel, New Delhi|9873777170Call Girls Near Delhi Pride Hotel, New Delhi|9873777170
Call Girls Near Delhi Pride Hotel, New Delhi|9873777170
 
(办理学位证)美国加州州立大学东湾分校毕业证成绩单原版一比一
(办理学位证)美国加州州立大学东湾分校毕业证成绩单原版一比一(办理学位证)美国加州州立大学东湾分校毕业证成绩单原版一比一
(办理学位证)美国加州州立大学东湾分校毕业证成绩单原版一比一
 
Tenets of Physiocracy History of Economic
Tenets of Physiocracy History of EconomicTenets of Physiocracy History of Economic
Tenets of Physiocracy History of Economic
 
Monthly Economic Monitoring of Ukraine No 231, April 2024
Monthly Economic Monitoring of Ukraine No 231, April 2024Monthly Economic Monitoring of Ukraine No 231, April 2024
Monthly Economic Monitoring of Ukraine No 231, April 2024
 
Stock Market Brief Deck for "this does not happen often".pdf
Stock Market Brief Deck for "this does not happen often".pdfStock Market Brief Deck for "this does not happen often".pdf
Stock Market Brief Deck for "this does not happen often".pdf
 
《加拿大本地办假证-寻找办理Dalhousie毕业证和达尔豪斯大学毕业证书的中介代理》
《加拿大本地办假证-寻找办理Dalhousie毕业证和达尔豪斯大学毕业证书的中介代理》《加拿大本地办假证-寻找办理Dalhousie毕业证和达尔豪斯大学毕业证书的中介代理》
《加拿大本地办假证-寻找办理Dalhousie毕业证和达尔豪斯大学毕业证书的中介代理》
 
call girls in Nand Nagri (DELHI) 🔝 >༒9953330565🔝 genuine Escort Service 🔝✔️✔️
call girls in  Nand Nagri (DELHI) 🔝 >༒9953330565🔝 genuine Escort Service 🔝✔️✔️call girls in  Nand Nagri (DELHI) 🔝 >༒9953330565🔝 genuine Escort Service 🔝✔️✔️
call girls in Nand Nagri (DELHI) 🔝 >༒9953330565🔝 genuine Escort Service 🔝✔️✔️
 
House of Commons ; CDC schemes overview document
House of Commons ; CDC schemes overview documentHouse of Commons ; CDC schemes overview document
House of Commons ; CDC schemes overview document
 
Bladex 1Q24 Earning Results Presentation
Bladex 1Q24 Earning Results PresentationBladex 1Q24 Earning Results Presentation
Bladex 1Q24 Earning Results Presentation
 
212MTAMount Durham University Bachelor's Diploma in Technology
212MTAMount Durham University Bachelor's Diploma in Technology212MTAMount Durham University Bachelor's Diploma in Technology
212MTAMount Durham University Bachelor's Diploma in Technology
 
SBP-Market-Operations and market managment
SBP-Market-Operations and market managmentSBP-Market-Operations and market managment
SBP-Market-Operations and market managment
 
Economic Risk Factor Update: April 2024 [SlideShare]
Economic Risk Factor Update: April 2024 [SlideShare]Economic Risk Factor Update: April 2024 [SlideShare]
Economic Risk Factor Update: April 2024 [SlideShare]
 
magnetic-pensions-a-new-blueprint-for-the-dc-landscape.pdf
magnetic-pensions-a-new-blueprint-for-the-dc-landscape.pdfmagnetic-pensions-a-new-blueprint-for-the-dc-landscape.pdf
magnetic-pensions-a-new-blueprint-for-the-dc-landscape.pdf
 
NO1 Certified Amil Baba In Lahore Kala Jadu In Lahore Best Amil In Lahore Ami...
NO1 Certified Amil Baba In Lahore Kala Jadu In Lahore Best Amil In Lahore Ami...NO1 Certified Amil Baba In Lahore Kala Jadu In Lahore Best Amil In Lahore Ami...
NO1 Certified Amil Baba In Lahore Kala Jadu In Lahore Best Amil In Lahore Ami...
 
(办理原版一样)QUT毕业证昆士兰科技大学毕业证学位证留信学历认证成绩单补办
(办理原版一样)QUT毕业证昆士兰科技大学毕业证学位证留信学历认证成绩单补办(办理原版一样)QUT毕业证昆士兰科技大学毕业证学位证留信学历认证成绩单补办
(办理原版一样)QUT毕业证昆士兰科技大学毕业证学位证留信学历认证成绩单补办
 
government_intervention_in_business_ownership[1].pdf
government_intervention_in_business_ownership[1].pdfgovernment_intervention_in_business_ownership[1].pdf
government_intervention_in_business_ownership[1].pdf
 

Jagran 2QFY15 Results Update Indicates Revenue and Profit Growth

  • 1. 29 October 2014 2QFY15 Results Update | Sector: Media Jagran Prakashan Shobhit Khare (Shobhit.Khare@MotilalOswal.com); +91 22 3982 5428 BSE SENSEX S&P CNX CMP: INR127 TP: INR165 Buy 27,098 8,090 Bloomberg JAGP IN Equity Shares (m) 326.9 M.Cap. (INR b) / (USD b) 41.6/0.7 52-Week Range (INR) 140/79 1, 6, 12 Rel. Per (%) 1/0/22 Financials & Valuation (INR Million) Y/E MAR 2015E 2016E 2017E Net Sales 18.3 20.3 22.2 EBITDA 4.5 5.2 5.7 Net Profit 2.4 3.0 3.4 EPS (INR) 7.7 9.5 11.0 EPS Gr. (%) 20.1 23.2 16.0 BV/Sh(INR) 34.0 38.8 45.1 RoE (%) 23.8 26.1 26.3 RoCE (%) 16.8 18.8 19.6 D.payout(%) 60.7 49.3 42.5 Valuations P/E (x) 16.5 13.4 11.5 P/BV (x) 3.7 3.3 2.8 EV/EBITDA (x) 9.1 7.7 6.7 D. Yield (%) 3.1 3.1 3.1  JAGP’s 2QFY15 EBITDA grew 16% YoY to INR1.06b (vs est of INR1.04b), supported by high single-digit growth in print advertising/circulation revenue and lower ‘other expenses’.  PAT grew 24% YoY to INR566m led by strong operating performance and higher other income, though offset by increased tax rate on a YoY basis. Tax rate increased 720bp YoY to 31% as the base period included tax benefits pertaining to the ‘Nai Duniya’ acquisition.  Ad revenue increased 8% YoY to INR3.07b (vs est of INR3.07b). Circulation revenue grew 7% YoY to INR965m (vs estimate of INR992m).  Consolidated revenue grew 5.4% YoY to INR4.36b (vs estimate of INR4.46b). The shortfall was largely on account of lower revenues from non-print segment.  Consolidated EBITDA margin increased 220bp YoY to 24.4%. RM cost increased ~9% YoY to INR1.6b (36.7% of revenue). We expect newsprint prices to correct going forward.  Other expenses declined 8% YoY on overall opex control, lower direct expenses in outdoor/event/digital and lower write-off/provision for bad debts. Valuation and view  Jagran’s 2QFY15 performance was broadly in line. We continue to expect strong earnings rebound in 2HFY15 led by acceleration in ad growth and decline in newsprint prices vs current levels.  We are upgrading PAT estimates by 1-3% on higher margin assumptions. We expect proforma EPS CAGR of 19% over FY14-17E driven by 10% ad revenue CAGR and EBITDA margin expansion of ~310 bps.  The stock trades at P/E of 16.5x FY15E and 13.4x FY16E. Maintain Buy with a price target of INR165 based on 16x average FY16/17 EPS. Investors are advised to refer through disclosures made at the end of the Research Report.
  • 2. 29 October 2014 2 Jagran Prakashan Standalone ad/circulation revenue (including Nai Duniya from 4QFY13) Source: Company, MOSL Standalone YoY ad growth (%) Source: Company, MOSL Standalone EBITDA (incl Nai Duniya from 4QFY13) Source: Company, MOSL RM/Sales (Consolidated from 1QFY14) Source: Company, MOSL 1,8981,9351,9451,8872,0432,1192,2352,1032,2072,1962,3932,2762,6852,6303,0002,6472,8802,8665535485705595826126236286416666997617958268618608969081QFY112QFY113QFY114QFY111QFY122QFY123QFY124QFY121QFY132QFY133QFY134QFY131QFY142QFY143QFY144QFY141QFY152QFY15 Advertising revenue (INR m)Circulation revenue (INR m) 18133120810151184701211151679 1QFY112QFY113QFY114QFY111QFY122QFY123QFY124QFY121QFY132QFY133QFY134QFY131QFY142QFY143QFY144QFY141QFY152QFY157058326536339029088977148207918516597887829115401013911109079710591033 30342927333331252726262125242616262425202625 1QFY102QFY103QFY104QFY101QFY112QFY113QFY114QFY111QFY122QFY123QFY124QFY121QFY132QFY133QFY134QFY131QFY142QFY143QFY144QFY141QFY152QFY15 EBITDA (INR m)EBITDA margin (%) 7016846746787568018639119891,0751,1351,0821,1351,1091,1791,2401,4161,4731,6271,5711,6271,603 30283029282930323235353536343436343636373737 1QFY102QFY103QFY104QFY101QFY112QFY113QFY114QFY111QFY122QFY123QFY124QFY121QFY132QFY133QFY134QFY131QFY142QFY143QFY144QFY141QFY152QFY15 RM cost (INR m)RM cost (% of rev)
  • 3. 29 October 2014 3 Jagran Prakashan Consolidated quarterly performance 2QFY14 1QFY15 2QFY15 YoY (%) QoQ (%) 2QFY15E v/s est (%) Advertising revenue 2,842 3,089 3,069 8.0 -0.6 3,069 0.0 Circulation revenue 899 957 965 7.3 0.9 992 -2.7 Others 396 357 329 -17.0 -8.1 400 -17.9 Revenue 4,137 4,403 4,363 5.4 -0.9 4,461 -2.2 Total operating cost 3,219 3,333 3,300 2.5 -1.0 3,418 -3.4 EBITDA 918 1,070 1,062 15.7 -0.7 1,044 1.8 EBITDA margin (%) 22.2 24.3 24.4 215bps 4bps 23.4 96bps Depreciation 190 238 245 29.0 3.1 238 3.1 EBIT 728 832 817 12.2 -1.8 806 1.4 Interest 78 84 73 -6.3 -12.3 84 -12.6 Other Income incl sale of property -55 69 71 -229.1 3.2 79 -9.8 PBT 595 818 815 37.1 -0.3 801 1.8 Tax 139 267 249 79.7 NA 261 NA Tax rate (%) 23 33 31 724bps -209bps 33 -209bps Reported PAT 456 551 566 24.1 2.8 539 4.9 Operating expenses (INR m) Raw material 1,473 1,627 1,603 8.8 -1.5 1,578 1.6 Employee 603 648 646 7.3 -0.2 651 -0.7 Others 1,143 1,058 1,051 -8.0 -0.6 1,188 -11.6 Total 3,219 3,333 3,300 2.5 -1.0 3,418 -3.4 Opex (% of revenue) Raw material 35.6 37.0 36.7 113bps -21bps Employee 14.6 14.7 14.8 25bps 10bps Others 27.6 24.0 24.1 -354bps 7bps Source: Company, MOSL Summary of estimate change (INR b) FY15E FY16E FY17E Revenue Old 18.52 20.61 22.51 New 18.32 20.34 22.16 Change (%) -1.1 -1.3 -1.5 EBITDA Old 4.38 5.06 5.60 New 4.52 5.15 5.66 Change (%) 3.0 1.9 1.1 EBITDA margin (%) Old 23.7 24.5 24.9 New 24.6 25.3 25.5 Change (bp) 97 80 65 Adj. PAT Old 2.33 2.89 3.39 New 2.40 2.96 3.43 Change (%) 3.1 2.3 1.2 Adj. EPS (INR) Old 7.5 9.3 10.9 New 7.7 9.5 11.0 Change (%) 3.1 2.3 1.2 Source: Company, MOSL
  • 4. 29 October 2014 4 Jagran Prakashan Key assumptions & other data FY10 FY11 FY12 FY13 FY14 FY15E FY16E FY17E Group ad revenue (INR b) 6.4 8.5 9.4 10.5 11.9 13.0 14.5 15.8 YoY (%) 16 34 10 12 13 9 12 9 -Standalone (exc. Nai Duniya) 6.4 7.7 8.5 8.9 10.0 11.0 12.4 13.5 YoY (%) 16 20 11 4 13 10 12 9 -Mid-Day + Inquilab 0.8 0.9 0.9 0.9 0.9 0.9 1.0 1.0 YoY (%) 4 2 -2 5 3 3 3 -Nai Duniya 0.8 0.9 1.0 1.2 1.3 YoY (%) 13 16 11 13 13 Group circulation revenue (INR b) 2.1 2.4 2.7 3.2 3.6 3.9 4.4 4.9 YoY (%) 9 12 11 20 12 9 13 11 -Standalone (exc. Nai Duniya) 2.1 2.2 2.4 2.7 3.1 3.4 3.8 4.3 YoY (%) 10 4 10 11 13 9 13 12 -Mid-Day + Inquilab 0.1 0.2 0.2 0.2 0.2 0.2 0.3 0.3 YoY (%) 4 28 9 5 9 9 8 -Nai Duniya 0.3 0.3 0.3 0.3 0.3 YoY (%) 25 10 10 10 0 Dainik Jagran av circulation/day (m) 2.7 3.0 3.2 3.5 3.6 3.9 4.1 4.3 YoY (%) -2 11 8 7 4 7 7 5 Newsprint price (USD/ton) 505 573 652 610 586 600 606 611 YoY (%) -20 13 14 -6 -4 2 1 1 RM cost/Revenue (%) 29 29 34 32 32 33 33 32 Revenue mix (%) Ad revenue 68 70 69 69 70 71 71 71 Circulation revenue 23 20 20 21 21 21 22 22 Other 10 11 11 10 9 8 7 6 Source: Company, MOSL
  • 5. 29 October 2014 5 Jagran Prakashan Jagran Prakashan: an investment profile Company description Jagran Prakashan Ltd (JPL) is a leading media and communications group with its main interests across Newspaper, Outdoor, Internet, Magazine, Event Management and Short Code Sevice media, spanning across 11 states. JPL is a leading newspaper publisher. It's flagship brand Dainik Jagran has been the largest read and circulated newspaper in India. JPL has 3 newspaper titles - Dainik Jagran, I next and City Plus. Dainik Jagran is a Hindi newspaper printed out of 31 locations across 11 states, I next is a bilingual compact morning newspaper targeted at 18-35 yrs, SEC AB1 in key metros, while City Plus is a weekly English tabloid circulated in Gurgaon, Faridabad, Ghaziabad, Noida and Delhi. Key investment argument  Strong presence in tier II/III towns across the Hindi speaking belt  Footprint expansion led by Mid-Day and 'Nai Duniya' acquisitions  High dividend pay-out Key investment risks  High exposure to the UP print market  Increased competition in UP and Bihar markets Recent developments  Jagran’s board approved a final dividend of INR3/sh. Valuation and view  We are upgrading PAT estimates by 1-3% on higher margin assumptions. We expect proforma EPS CAGR of 19% over FY14-17E driven by 10% ad revenue CAGR and EBITDA margin expansion of ~310 bps.  The stock trades at P/E of 16.5x FY15E and 13.4x FY16E. Maintain Buy with a price target of INR165 based on 16x average FY16/17 EPS. Comparative valuations Jagran HT Media DB Corp P/E (x) FY15E 16.6 13.3 18.3 FY16E 13.5 11.7 15.5 EV/EBITDA (x) FY15E 9.1 5.5 10.3 FY16E 7.7 4.2 8.7 Div. Yield (%) FY15E 3.1 0.3 2.4 FY16E 3.1 0.4 2.9 P/BV (x) FY15E 3.8 1.2 5.0 FY16E 3.3 1.1 4.3 EPS: MOSL forecast v/s consensus (INR) MOSL Consensus Variation Forecast Forecast (%) FY15 7.7 8.1 -5.4 FY16 9.5 9.8 -3.0 Target price and recommendation Current Target Upside Reco. Price (INR) Price (INR) (%) 127 165 29.9 Buy Shareholding pattern (%) Jun-14 Mar-14 Jun-13 Promoter 62.6 62.6 61.6 DII 9.5 9.1 12.3 FII 15.1 14.0 12.7 Others 12.8 14.4 13.3 Note: FII Includes depository receipts Stock performance (1-year) 7593111129147Oct-13Jan-14Apr-14Jul-14Oct-14Jagran PrakashanSensex -Rebased
  • 6. 29 October 2014 6 Jagran Prakashan Financials and valuation Income Statement (Consolidated)(INR Million) Y/E March20142015E2016E2017ENet Sales 17,02718,32320,33722,163YoY (%)11.67.611.09.0EBITDA3,8264,5165,1535,660EBITDA margin (%)22.524.625.325.5Depreciation789974928925Interest345335326326Other Income117359492684PBT2,8103,5654,3905,092Tax7951,1641,4331,662Tax rate (%)28.332.632.632.6Adjusted PAT2,0152,4012,9573,430 Change (%)36.619.223.216.0Extra-ordinary items248000Reported PAT2,2632,4012,9573,430Balance SheetY/E March20142015E2016E2017EShare Capital623623623623Share Premium3,1253,1253,1253,125Reserves5,8696,8138,31410,287Net Worth9,61610,56112,06114,034Loans4,6584,6584,6584,658Deffered Tax Liability854854854854Minority interest9999Capital Employed 15,13716,08217,58219,555Gross Fixed Assets11,23211,96512,77813,665Less: Depreciation4,8235,7976,7257,651Net Fixed Assets6,4096,1676,0536,014Capital WIP316316316316Goodwill2,3232,3232,3232,323Investments3,3203,3203,3203,320Curr. Assets6,8888,38710,48912,943Inventory9991,0901,1911,281Debtors3,4263,7654,1794,554Cash & Bank Balance3251,2312,5664,326Loans & Advances1,4651,5771,7501,907Other current assets673724803875Current Liab. & Prov.4,1194,4324,9195,361Creditors2,8793,0983,4383,747Provisions & other liabilitie1,2401,3351,4811,614Net Current Assets 2,7693,9555,5707,582Application of Funds15,13716,08217,58219,555E: MOSL EstimatesRatiosY/E March20142015E2016E2017EBasic (INR) Adjusted EPS 6.47.79.511.0Growth (%)37.720.123.216.0Cash EPS 8.910.812.514.0Book Value30.734.038.845.1DPS4.04.04.04.0Payout (incl. Div. Tax.) (%)72614942ValuationP/E 19.816.513.411.5Cash P/E14.211.710.29.1EV/EBITDA10.99.17.76.7EV/Sales2.52.21.91.7Price/Book Value4.13.73.32.8Dividend Yield (%)3.13.13.13.1Profitability Ratios (%) RoE21.323.826.126.3RoCE 16.716.818.819.6Turnover RatiosDebtors (Days)73757575Inventory (Days)21222121Creditors. (Days)80828383Asset Turnover (x)1.51.61.81.9Leverage RatioDebt/Equity (x)0.50.40.40.3Cash Flow Statement(INR Million) Y/E March20142015E2016E2017EOp.Profit/(Loss) bef Tax3,8264,5165,1535,660Other Income117359492684Interest Paid-345-335-326-326Direct Taxes Paid-795-1,164-1,433-1,662(Inc)/Dec in Wkg. Cap.372-280-280-253CF from Op.Activity3,1763,0963,6054,102(inc)/Dec in FA + CWIP-768-733-813-887(Pur)/Sale of Investments-1,096000CF from Inv.Activity-1,864-733-813-887Inc/(Dec) in Debt35000Dividends Paid-1,457-1,457-1,457-1,457Other Financing Activities-2000CF from Fin.Activity-1,899-1,457-1,457-1,457Inc/(Dec) in Cash-5889061,3351,759Add: Opening Balance5233251,2312,566Closing Balance3251,2312,5664,326
  • 7. 29 October 2014 7 Jagran Prakashan N O T E S
  • 8. 29 October 2014 8 Jagran Prakashan Disclosures This research report has been prepared by MOSt to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its affiliated company(ies). This report is for personal information of the select recipient and does not construe to be any investment, legal or taxation advice to you. This research report does not constitute an offer, invitation or inducement to invest in securities or other investments and Motilal Oswal Securities Limited (hereinafter referred as MOSt) is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your general information and should not be reproduced or redistributed to any other person in any form. This report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, investors should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. MOSt and its affiliates are a full-service, integrated investment banking, investment management, brokerage and financing group. We and our affiliates have investment banking and other business relationships with a significant percentage of the companies covered by our Research Department Our research professionals provide important input into our investment banking and other business selection processes. Investors should assume that MOSt and/or its affiliates are seeking or will seek investment banking or other business from the company or companies that are the subject of this material and that the research professionals who were involved in preparing this material may participate in the solicitation of such business. The research professionals responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting market information. Our research professionals are paid in part based on the profitability of MOSt which include earnings from investment banking and other business. MOSt generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, MOSt generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover. Our salespeople, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all o the foregoing, among other things, may give rise to real or potential conflicts of interest . MOSt and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. Unauthorized disclosure, use, dissemination or copying (either whole or partial) of this information, is prohibited. The person accessing this information specifically agrees to exempt MOSt or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOSt or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOSt or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays. The information contained herein is based on publicly available data or other sources believed to be reliable. Any statements contained in this report attributed to a third party represent MOSt’s interpretation of the data, information and/or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party. This Report is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. While we would endeavor to update the information herein on reasonable basis, MOSt and/or its affiliates are under no obligation to update the information. Also there may be regulatory, compliance, or other reasons that may prevent MOSt and/or its affiliates from doing so. MOSt or any of its affiliates or employees shall not be in any way responsible and liable for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. MOSt or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations. Recipients who are not institutional investors should seek advice of their independent financial advisor prior to taking any investment decision based on this report or for any necessary explanation of its contents. MOSt and/or its affiliates and/or employees may have interests/positions, financial or otherwise in the securities mentioned in this report. To enhance transparency, MOSt has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. Disclosure of Interest Statement JAGRAN PRAKASHAN LTD  Analyst ownership of the stock No Analyst Certification The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The research analysts, strategists, or research associates principally responsible for preparation of MOSt research receive compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues. Regional Disclosures (outside India) This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOSt & its group companies to registration or licensing requirements within such jurisdictions. For U.K. This report is intended for distribution only to persons having professional experience in matters relating to investments as described in Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (referred to as "investment professionals"). This document must not be acted on or relied on by persons who are not investment professionals. Any investment or investment activity to which this document relates is only available to investment professionals and will be engaged in only with such persons. For U.S. Motilal Oswal Securities Limited (MOSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition MOSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement. The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account. For Singapore Motilal Oswal Capital Markets Singapore Pte Limited is acting as an exempt financial advisor under section 23(1)(f) of the Financial Advisers Act(FAA) read with regulation 17(1)(d) of the Financial Advisors Regulations and is a subsidiary of Motilal Oswal Securities Limited in India. This research is distributed in Singapore by Motilal Oswal Capital Markets Singapore Pte Limited and it is only directed in Singapore to accredited investors, as defined in the Financial Advisers Regulations and the Securities and Futures Act (Chapter 289), as amended from time to time. In respect of any matter arising from or in connection with the research you could contact the following representatives of Motilal Oswal Capital Markets Singapore Pte Limited: Anosh Koppikar Kadambari Balachandran Email : anosh.Koppikar@motilaloswal.com Email : kadambari.balachandran@motilaloswal.com Contact : (+65)68189232 Contact : (+65) 68189233 / 65249115 Office Address : 21 (Suite 31),16 Collyer Quay,Singapore 04931 Motilal Oswal Securities Ltd Motilal Oswal Tower, Level 9, Sayani Road, Prabhadevi, Mumbai 400 025 Phone: +91 22 3982 5500 E-mail: reports@motilaloswal.com